Conagra Brands, Inc. (NYSE: CAG) is a Chicago-based consumer packaged foods company behind brands such as Birds Eye, Marie Callender's, Healthy Choice, Banquet, Duncan Hines, Hunt's, Slim Jim, and Orville Redenbacher's. After a difficult stretch in which the stock slid from a 52-week high of $20.32 to a low near $12.53, shares have recovered to roughly $16, leaving investors to ask whether a move back toward and beyond the prior peak — and ultimately toward $25 — is realistic.
The $25 mark is significant because it sits above the stock's recent all-time trading zone, above the highest Street price target of $23, and roughly in line with several independent valuation estimates that place Conagra's intrinsic value in the mid-$20s. Reaching it would require the market to fully price in a successful turnaround, rather than merely a stabilization.
Conagra's fundamentals reflect a mature business under pressure. In fiscal 2026, which ended May 31, 2026, net sales fell about 2.9% to $11.28 billion, continuing a multiyear decline. The company reported a diluted loss per share of $4.00 for the year, driven largely by non-cash impairment charges, while adjusted earnings were closer to $1.72 per share. Total debt stands at roughly $7.3 billion, and the company's largest customer, Walmart (NYSE: WMT), accounts for approximately 29% of consolidated net sales, underscoring concentration risk.
The company's market capitalization is around $7.7 billion, and the shares trade at a low single-digit forward price-to-earnings (P/E) multiple — a valuation that reflects both the stock's defensive income appeal and the market's skepticism about future growth.
The clearest catalyst behind the $25 discussion is Conagra's strategic reset, announced in July 2026 under new Chief Executive Officer John Brase. As part of the plan, management cut the dividend by roughly 50%, a move expected to free about $335 million annually for debt reduction, increased brand investment, and supply-chain modernization. The company also outlined a shift in its frozen foods business away from pure volume growth and toward protecting margins through pricing, alongside a broader effort to simplify its product portfolio.
If these initiatives gradually restore profitability and stabilize volumes, the resulting earnings recovery could justify a meaningfully higher valuation. At a normalized multiple on improved earnings, a share price approaching the mid-$20s becomes a plausible multiyear outcome — though it is far from guaranteed.
The analyst community remains cautious. The consensus rating is Hold, and the average 12-month price target sits near $14.38 — below the current share price. Targets range from a low of $12 (reflecting sell ratings from firms such as Bernstein and Goldman Sachs) to a high of $23. Barclays is among the more constructive voices, with an Overweight rating and a $17 target, while J.P. Morgan, UBS, and RBC Capital have issued Hold ratings with targets in the $14 to $15 range.
Notably, even the most bullish Street target of $23 falls short of $25, meaning the selected objective currently represents a level above consensus expectations. For CAG to reach $25, analysts would need to significantly raise their earnings forecasts and target prices — something that would likely require multiple quarters of improving results.
From a technical perspective, Conagra has established a durable support zone near its 52-week low around $12.53, with additional support clustered in the $14 area. On the upside, the prior high of $20.32 acts as the first major resistance level; a decisive move through that zone would confirm a recovery trend and open the path toward higher psychological levels.
Because $25 sits above the stock's previous record trading zone, there is limited historical supply overhead to weigh on price in that region. However, reaching it would require the shares to first reclaim and hold the $20 level — a hurdle the stock has not sustained since early 2026.
Several obstacles stand between Conagra and a $25 price target. Inflation in key inputs such as beef, edible oils, and logistics remains a headwind, and consumers continue to trade down toward value offerings. Organic sales have been declining, and the dividend cut — while freeing cash for reinvestment — removed one of the primary reasons income investors held the stock. Persistently weak volumes, a leveraged balance sheet, and execution risk on the turnaround all argue for caution. Until the company demonstrates that the strategic reset is translating into stable or growing adjusted earnings, the shares are unlikely to command the higher multiple that a $25 price would imply.
For traders seeking a data-driven edge, Tickeron's AI Daily Buy/Sell Signals offer a way to monitor shifting conditions across thousands of stocks and ETFs. The tool uses artificial intelligence to generate Buy, Sell, or Hold signals based on technical behavior, market dynamics, and AI-driven analysis, helping users spot opportunities and track changing trends more efficiently. As Conagra's turnaround story develops, signals of this kind can provide an additional lens for evaluating whether momentum is genuinely building or fading. Explore Tickeron's AI Daily Buy/Sell Signals to see how automated analysis fits into your market routine.
A move to $25 is not impossible, but it currently appears optimistic relative to both the analyst consensus and the company's near-term fundamentals. The strongest arguments in its favor are the discounted valuation, the new leadership team, and a strategic reset that prioritizes debt reduction and reinvestment over dividends. The primary risks are continued volume declines, input-cost inflation, and the absence of any Street target above $23. For investors, the key variables to monitor are whether organic sales stabilize, whether adjusted earnings begin to grow again, and whether the shares can reclaim and hold the $20 resistance level. A sustained recovery on those fronts would bring $25 into view; without it, the target is likely to remain out of reach.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
A.I.dvisor indicates that over the last year, CAG has been closely correlated with GIS. These tickers have moved in lockstep 78% of the time. This A.I.-generated data suggests there is a high statistical probability that if CAG jumps, then GIS could also see price increases.
| Ticker / NAME | Correlation To CAG | 1D Price Change % |
|---|---|---|
| CAG | 100% | +1.30% |
| CAG (4 stocks) | 67% Closely correlated | +0.74% |
| Food: Major Diversified (63 stocks) | 3% Poorly correlated | -0.17% |